Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation

Journal of Cardiovascular Electrophysiology

Volumn 27, Issue 2, 2016, Pages 147-153

  Rillig, Andreas ^a   Lin, Tina ^a   Plesman, Joaquina ^a   Heeger, Christian H ^a   Lemes, Christine ^a   Metzner, Andreas ^a   Mathew, Shibu ^a   Wissner, Erik ^a   Wohlmuth, Peter ^b   Ouyang, Feifan ^a   Kuck, Karl Heinz ^a   Tilz, Roland Richard ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b Asklepios Proresearch   (Germany)

Author keywords

anticoagulation; apixiban; atrial fibrillation; bleeding; catheter ablation; complication; dabigatran; novel oral anticoagulant; pulmonary vein isolation; rivaroxaban

Indexed keywords

APIXABAN; DABIGATRAN; HEMOGLOBIN; PHENPROCOUMON; RIVAROXABAN; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ANEURYSM; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; DYSPNEA; FEMALE; FEMORAL ARTERY ANEURYSM; GROIN HEMATOMA; HEART TAMPONADE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; ACTION POTENTIAL; ADVERSE EFFECTS; AGED; CATHETER ABLATION; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; HEART FUNCTION TEST; HEART RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; REGISTER; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ACTION POTENTIALS; ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CATHETER ABLATION; DABIGATRAN; DRUG ADMINISTRATION SCHEDULE; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FACTOR XA INHIBITORS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PHENPROCOUMON; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; PYRIDONES; REGISTRIES; RIVAROXABAN; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84956658162     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/jce.12856     Document Type: Article

References (31)

1. Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Köktürk B, Konstantinidou M, Metzner A, Fuernkranz A, Kuck K-H,: Long-term results of catheter ablation in paroxysmal atrial fibrillation: Lessons from a 5-year follow-up. Circulation 2010; 122: 2368-2377.
2. Tilz RR, Rillig A, Thum A-M, Arya A, Wohlmuth P, Metzner A, Mathew S, Yoshiga Y, Wissner E, Kuck K-H, Ouyang F,: Catheter ablation of long-standing persistent atrial fibrillation: 5-Year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol 2012; 60: 1921-1929.
3. Rillig A, Lin T, Schmidt B, Feige B, Heeger C, Wegner J, Wissner E, Metzner A, Arya A, Mathew S, Wohlmuth P, Ouyang F, Kuck K-H, Tilz RR,: Experience matters: Long-term results of pulmonary vein isolation using a robotic navigation system for the treatment of paroxysmal atrial fibrillation. Clin Res Cardiol 2015. [Epub ahead of print].
4. Rillig A, Makimoto H, Wegner J, Lin T, Heeger C, Lemes C, Fink T, Metzner A, Wissner E, Mathew S, Wohlmuth P, Kuck K-H, Tilz RR, Ouyang F,: Six-year clinical outcomes after catheter ablation of atrial fibrillation in patients with impaired left ventricular function. J Cardiovasc Electrophysiol 2015. doi: 10.1111/jce.12765. [Epub ahead of print].
5. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J, Kim Y-H, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E,: Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2010; 3: 32-38.
6. Rillig A, Schmidt B, Feige B, Wissner E, Metzner A, Arya A, Mathew S, Makimoto H, Wohlmuth P, Ouyang F, Kuck K-H, Tilz RR,: Left atrial isthmus line ablation using a remote robotic navigation system: Feasibility, efficacy and long-term outcome. Clin Res Cardiol 2013; 102: 885-893.
7. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D,: 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14: 528-606.
8. Nührich JM, Kuck K-H, Andresen D, Steven D, Spitzer SG, Hoffmann E, Schumacher B, Eckardt L, Brachmann J, Lewalter T, Hochadel M, Senges J, Willems S, Hoffmann BA,: Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: Data from the German Ablation Registry. Clin Res Cardiol 2014; 104: 463-470.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L,; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM,; ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
11. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L,; ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
12. Eitel C, Koch J, Sommer P, John S, Kircher S, Bollmann A, Arya A, Piorkowski C, Hindricks G,: Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013; 15: 1587-1593.
13. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A,: Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol 2012; 59: 1168-1174.
14. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, Hayano M, Nishiuchi S, Fuke E, Miki Y, Nakamura K, Yamashita E, Kumagai K, Oshima S, Tada H,: Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012; 76: 2337-2342.
15. Hayashi T, Kumagai K, Naito S, Goto K, Kaseno K, Ohshima S, Hachiya H, Hirao K, Isobe M,: Preprocedural therapeutic international normalized ratio influence on bleeding complications in atrial fibrillation ablation with continued anticoagulation with warfarin. Circ J 2013; 77: 338-344.
16. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D, Verma A, Khaykin Y, Hongo R, Hao S, Beheiry S, Pelargonio G, Russo Dello A, Casella M, Santarelli P, Santangeli P, Wang P, Al-Ahmad A, Patel D, Themistoclakis S, Bonso A, Rossillo A, Corrado A, Raviele A, Cummings JE, Schweikert RA, Lewis WR, Natale A,: Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550-2556.
17. Lip GYH, Proclemer A, Dagres N, Bongiorni MG, Lewalter T, Blomström-Lundqvist C,; Scientific Initiative Committee, European Heart Rhythm Association: Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation. Europace 2012; 14: 741-744.
18. Providencia R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, Hireche H, Morais J, Boveda S,: Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace 2014; 16: 1137-1144.
19. Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H, Ishikawa S, Miyoshi A, Okumura S, Ohguchi S, Yamamoto T, Yoshida N, Hirai M, Murohara T,: Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Pacing Clin Electrophysiol 2015; 38: 155-163.
20. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan G-A, Gulizia M, Halvorsen S, Hindricks G, Kuck K-H, Moya A, Potpara T, Roldan V, Tilz R, Lip GYH, Document Reviewers, Gorenek B, Indik JH, Kirchhof P, Ma C-S, Narasimhan C, Piccini J, Sarkozy A, Shah D, Savelieva I,: Antithrombotic management in patients undergoing electrophysiological procedures: A European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 2015.
21. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Russo Dello A, Casella M, Fassini G, Tondo C, Schweikert RA, Natale A,: Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014; 129: 2638-2644.
22. Kwak J-J, Pak H-N, Jang J-K, Kim SK, Park JH, Choi J-I, Hwang C, Kim Y-H,: Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2010; 21: 620-625.
23. Garton AB, Dudzinski J, Kowey PR,: Oral anticoagulant use around the time of atrial fibrillation ablation: A review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis. J Cardiovasc Electrophysiol 2014; 25: 1411-1418.
24. Chen J, Todd DM, Hocini M, Larsen TB, Bongiorni MG, Blomstrom-Lundqvist C,; Conducted by the Scientific Initiative Committee, European Heart Rhythm Association: Current periprocedural management of ablation for atrial fibrillation in Europe: Results of the European Heart Rhythm Association survey. Europace 2014; 16: 378-381.
25. Mardigyan V, Verma A, Birnie D, Guerra P, Redfearn D, Becker G, Champagne J, Sapp J, Gula L, Parkash R, Macle L, Crystal E, O'Hara G, Khaykin Y, Sturmer M, Veenhuyzen GD, Greiss I, Sarrazin J-F, Mangat I, Novak P, Skanes A, Roux J-F, Chauhan V, Hadjis T, Morillo CA, Essebag V,: Anticoagulation management pre- and post atrial fibrillation ablation: A survey of Canadian centres. Can J Cardiol 2013; 29: 219-223.
26. Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, Gunter A, McElderry HT,: Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013; 24: 861-865.
27. Shurrab M, Morillo CA, Schulman S, Kansal N, Danon A, Newman D, Lashevsky I, Healey JS, Crystal E,: Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: A meta-analysis. Can J Cardiol 2013; 29: 1203-1210.
28. Hohnloser SH, Camm AJ,: Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: A meta-analysis of the literature. Europace 2013; 15: 1407-1411.
29. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA,: The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268.
30. Page SP, Herring N, Hunter RJ, Withycombe E, Lovell M, Wali G, Betts TR, Bashir Y, Dhinoja M, Earley MJ, Sporton SC, Rajappan K, Schilling RJ,: Periprocedural stroke risk in patients undergoing catheter ablation for atrial fibrillation on uninterrupted warfarin. J Cardiovasc Electrophysiol 2014; 25: 585-590.
31. Seivani Y, Abdel-Wahab M, Geist V, Richardt G, Sulimov DS, El-Mawardy M, Toelg R, Akin I,: Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol 2013; 102: 799-806.